HGS drug doesn't extend survival for lung cancer patients in study

03/18/2010 | Reuters

Cancer drug mapatumumab did not boost the efficacy of chemotherapy drugs paclitaxel and carboplatin in improving progression-free survival for patients with nonsmall-cell lung cancer during a midstage trial. Human Genome Sciences, maker of mapatumumab, tested the combination as a first-line therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY